Nature of practice and clients
Arnold & Porter LLP is one of America's leading law firms, with more than 800 lawyers practising in Washington, DC, and eight other domestic and international offices in virtually every transactional, regulatory, and dispute resolution discipline. Headquartered in Washington, DC, our firm has a long history of representing clients in highly regulated industries throughout the United States, Europe, and globally, including interfacing with governmental agencies and representing clients who contract with the government.
For decades, Arnold & Porter's Pharmaceutical and Medical Device practice has been a leader in helping pharmaceutical, biotechnology, medical device, and diagnostic companies, as well as other healthcare entities, respond to complex regulatory and compliance challenges. We assist our clients in routine counseling matters, resolving their issues and concerns and supporting key business operations, as well as in the most complex global investigations and crises - all with an eye on their long-term business and product goals. Our practice also has substantial experience in the regulatory issues faced by food, dietary supplement, and cosmetic product companies.
Firm recognition includes:
- VAULT Guide's Top 100 Law Firms (2004 to 2012).
- Chambers USA 2013 ranked 85 attorneys Leading Individuals in 39 practice areas.
- Chambers Global 2013 ranked 37 attorneys in 18 practice areas.
- The Legal 500 US 2013 ranked Arnold & Porter as a leading firm in 20 practice areas.
- The American Lawyer's A-List: seven years.
- Chambers Latin America 2013 named Arnold & Porter a leading firm.
Arnold & Porter555 Twelfth Street, NWWashington, DC 20004-1206United StatesT+1 202 942 5000F+1 202 942 5999
- Arnold & PorterTower 4225 Old Broad StreetLondon, EC2N 1HQUnited Kingdom
- EU and US regulation of health information technology, software and mobile apps
- The US Caronia case: truthful off-label communications by pharmaceutical companies
- The US Physician Payment Sunshine Act: implications for multinational drug and device manufacturers
- Risk management of pharmaceuticals in the EU and US - trends and analysis
- Intellectual property rights: the key issues
- Merger remedies in the EU and US
- Cartel prosecution in the US and the EU - recent developments
- Competition: Market definition: The Commission guidelines